Analysts Defend Merck Amid Investor Concerns Over Weak Guidance
Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a lower-than-expected 2025 outlook. Latest Ratings for MRK Date Firm Action From To Feb 2022 SVB Leerink Maintains Outperform Jan 2022 JP Morgan Maintains Overweight Dec 2021 Daiwa Capital Initiates Coverage On Neutral View More Analyst Ratings…